Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | BCL3 | P20749 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362567 | 0.86 | POLB (0.66) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL7526242 | 0.84 | POLB (0.66) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL7638428 | 0.83 | POLB (0.55) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL12305552 | 0.83 | POLB (0.62) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| Hydrochloric Acid SCHEMBL7641302 | 0.82 | POLB (0.54) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL10352602 | 0.82 | POLB (0.65) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL1382764 | 0.80 | SMN1; SMN2 (0.95) | POLBALDH1A1KDM4ESMN1; SMN2TSHR | |
| SCHEMBL12333392 | 0.80 | POLB (0.62) | POLBALDH1A1KDM4ELMNAGLA | |
| SCHEMBL13385672 | 0.80 | POLB (0.61) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 | |
| SCHEMBL14525845 | 0.80 | POLB (0.71) | POLBALDH1A1KDM4ESMN1; SMN2BCL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | POLB 2674/4885ALDH1A1 1869/4885KDM4E 2939/4885 |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | POLB 2380/4885ALDH1A1 820/4885KDM4E 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.